logo
Plus   Neg
Share
Email

Jounce Therapeutics Inc. (JNCE) Plunged To A New Low On Study Results

Jounce Therapeutics Inc. (JNCE) reported disappointing preliminary results from its ongoing Phase 1/2 trial of JTX-2011 alone and in combination with nivolumab in patients with advanced solid tumors Monday morning.

Jounce Therapeutics gapped open lower Monday and dropped sharply in the first hour of trade. Shares finished with a loss of 3.76 at $7.47 on strong volume. The stock tumbled to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

RELATED NEWS
Follow RTT
>